Evaluation of the nephroprotective role of cystone in patients receiving cisplatin-based chemotherapy

Abstract

Objectives: Nephrotoxicity is a well-recognised dose-limiting adverse effect of cisplatin. Cystone is a polyherbal formulation with some evidence suggesting it may mitigate cisplatin-induced acute kidney injury (CIAKI). Purpose: To assess the incidence of CIAKI between the two study arms, to assess the need for a dose modification after Cystone use, and to assess the difference in values of kidney function tests, outside the definition of acute kidney injury. Materials and Methods: In a prospective randomised controlled trial conducted at Ain Shams University Hospitals, 99 patients undergoing cisplatin-based chemotherapy were randomly assigned to either a Cystone group (two tablets, 3 times daily throughout chemotherapy) or a control group. Results: There was no statistically significant difference in CIAKI incidence between the two groups (25% in the Cystone group vs. 34% in controls). Dose modification rates were also comparable (10.4% vs. 12%). However, kidney function, as measured by serum creatinine and creatinine clearance, significantly worsened in the control group. Conclusion: Although Cystone did not significantly reduce CIAKI incidence, the greater renal function decline in the control group warrants further investigation into its potential nephroprotective properties.